BioVie Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week announced that its Phase 2 long COVID trial evaluating bezisterim has achieved full enrollment, marking an important milestone for the biotechnology company as it advances a potential treatment for patients suffering persistent post-COVID...
BioVie CEO Cuong Do joined Steve Darling from Proactive to announce the successful completion of patient enrollment for the company’s ADDRESS-LC Phase 2 clinical study evaluating its drug candidate bezisterim for the treatment of neurological symptoms associated with Long COVID. The study marks an important milestone for the company and is fully funded through a grant from the U.S. Department of Defense, helping advance the program without additional financing pressures tied directly to the trial. Do highlighted the growing healthcare challenge posed by Long COVID, which continues to affect millions of individuals long after their initial infection. According to estimates, approximately 15 million adults in the United States reported experiencing Long COVID between 2022 and 2023, with roughly 3.8 million indicating that symptoms significantly interfered with their daily activities and quality of life. The persistence of symptoms has created an increasing need for effective treatment options and greater clinical understanding of the condition. He explained that nearly half of individuals experiencing Long COVID develop symptoms that can persist either continuously or intermittently over extended periods. Among the most common and debilitating complications are neurological symptoms, which often include fatigue, cognitive impairment commonly referred to as “brain fog,” persistent cognitive dysfunction, post-exertional malaise, and sleep disturbances. These symptoms can create significant physical and emotional challenges for patients and have emerged as one of the major areas of focus in Long COVID research. BioVie noted that advancing scientific understanding continues to strengthen the rationale for bezisterim’s proposed mechanism of action. The company believes that growing evidence increasingly points to chronic inflammation and ongoing immune system activity as key contributors to many Long COVID symptoms, particularly those affecting neurological and neuropsychiatric function. Bezisterim is designed to target inflammatory pathways that may be driving these persistent symptoms. Despite growing awareness of Long COVID and increasing research efforts, treatment options remain limited. BioVie emphasized that there are currently no FDA-approved therapies specifically designed to treat Long COVID, leaving a significant unmet medical need and potentially creating a substantial opportunity for therapies capable of addressing the condition effectively. proactiveinvestors #biovieince #nasdaq #bivi #LongCOVID #ClinicalTrials #Biotech #DrugDevelopment #MedicalResearch #Neurology #HealthcareInnovation #Phase2Trial #Biopharma
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Tuesday it has completed enrollment in its ADDRESS-LC Phase 2 clinical trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID, with topline data expected later this summer. The trial, fully funded by a grant from the...
-Topline Data Release Targeted Late Summer 2026-CARSON CITY, Nev., May 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) has completed the last patient evaluation visit in its SUNRISE-PD Phase 2 clinical trial testing drug candidate bezisterim in early-stage Parkinson's disease, with topline results expected in the third quarter. The NASDAQ-listed clinical-stage company...
"With this last patient's treatment visit completed, our team will start the study closeout process, and the Company plans announce topline results in Q3," said Cuong Do, BioVie's President and CEO. "This trial was
CARSON CITY, Nev., May 18, 2026 -- BioVie Inc. , a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the last...
BioVie Inc. (BIVI) Discusses Bezisterim's Mechanism of Action and Its Potential in Addressing Parkinson's Disease Pathology May 7, 2026 2:00 PM EDTCompany...
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week outlined progress in its clinical program targeting long COVID, highlighting both the scale of the unmet need and the potential for a first-in-class treatment. In an interview with Proactive, CEO Cuong Do said that approximately 17...
Presentation Operator MessageOperator Good afternoon, and welcome to the BioVie Virtual KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made...
BioVie CEO Cuong Do joined Steve Darling from Proactive to provide an update on the company’s ongoing clinical efforts targeting long COVID, a condition that continues to affect an estimated 17 million Americans despite the acute phase of the COVID-19 pandemic having subsided. Do emphasized that long COVID remains a significant and persistent public health challenge, with many patients experiencing debilitating symptoms such as brain fog, chronic fatigue, and general malaise that can severely impact daily functioning and quality of life. He noted that unlike the initial viral infection, long COVID appears to involve lingering viral protein fragments or related biological remnants that may continue to stimulate the immune system even after the virus has been cleared from the body. This ongoing immune activation is believed to contribute to sustained inflammation, which in turn may drive the neurological and systemic symptoms associated with the condition. BioVie Inc. is focusing its research efforts specifically on addressing these central nervous system-related symptoms through a targeted therapeutic approach. Do highlighted that the company’s program is supported by a $13 million clinical research grant, underscoring both the importance and urgency of developing effective treatments in this area. He also noted that BioVie is uniquely positioned in this space, stating that it is “the only company, nonprofit, any kind of organization to have received a grant to do this,” reinforcing the distinct nature of its clinical work. The company’s clinical trial is now nearing completion of patient enrollment, with top-line data expected by the end of the summer. This represents a key near-term milestone for the program as it moves toward evaluating efficacy and safety outcomes. Importantly, Do pointed out that there are currently no approved therapies specifically designed to treat long COVID, positioning BioVie’s program as a potential first-in-class treatment option in a space with significant unmet medical need. He expressed optimism about the trial’s progress and the potential impact of a successful outcome for patients who are still unable to return to normal daily activities or work due to lingering symptoms. proactiveinvestors #biovieince #nasdaq #bivi #LongCOVID #PostCOVID #ChronicFatigue #BrainFog #Neuroinflammation #ClinicalTrials #Biotech #CNSResearch #HealthcareInnovation #MedicalResearch #PublicHealth #Inflammation #DrugDevelopment #UnmetNeed
BioVie CEO Cuong Do joined Steve Darling from Proactive to provide an update on the company’s ongoing clinical efforts targeting long COVID, a condition that continues to affect an estimated 17 million Americans despite the acute phase of the COVID-19 pandemic having subsided. Do emphasized that long COVID remains a significant and persistent public health challenge, with many patients experiencing debilitating symptoms such as brain fog, chronic fatigue, and general malaise that can severely impact daily functioning and quality of life. He noted that unlike the initial viral infection, long COVID appears to involve lingering viral protein fragments or related biological remnants that may continue to stimulate the immune system even after the virus has been cleared from the body. This ongoing immune activation is believed to contribute to sustained inflammation, which in turn may drive the neurological and systemic symptoms associated with the condition. BioVie Inc. is focusing its research efforts specifically on addressing these central nervous system-related symptoms through a targeted therapeutic approach. Do highlighted that the company’s program is supported by a $13 million clinical research grant, underscoring both the importance and urgency of developing effective treatments in this area. He also noted that BioVie is uniquely positioned in this space, stating that it is “the only company, nonprofit, any kind of organization to have received a grant to do this,” reinforcing the distinct nature of its clinical work. The company’s clinical trial is now nearing completion of patient enrollment, with top-line data expected by the end of the summer. This represents a key near-term milestone for the program as it moves toward evaluating efficacy and safety outcomes. Importantly, Do pointed out that there are currently no approved therapies specifically designed to treat long COVID, positioning BioVie’s program as a potential first-in-class treatment option in a space with significant unmet medical need. He expressed optimism about the trial’s progress and the potential impact of a successful outcome for patients who are still unable to return to normal daily activities or work due to lingering symptoms. proactiveinvestors #biovieince #nasdaq #bivi #LongCOVID #PostCOVID #ChronicFatigue #BrainFog #Neuroinflammation #ClinicalTrials #Biotech #CNSResearch #HealthcareInnovation #MedicalResearch #PublicHealth #Inflammation #DrugDevelopment #UnmetNeed
CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it will host a virtual key opinion leader (KOL) event on Thursday, May 7, 2026 at 2:00 PM ET featuring Suzanne de la Monte, MD, MPH (Brown University Warren Alpert Medical School, Providence VA Medical Center), who will join company management to discuss how
BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it will host a virtual key
United Rentals (URI) stock rose in pre-market trading after reporting better-than-expected earnings and raising its FY26 sales guidance. Other gainers include PAPL, AKAN, YCBD, SST, MEHA, QS, BIVI, TRT, and TXN. Losers include ASGN, AGPU, AEHL, and ME.
ORLANDO, FL / ACCESS Newswire / April 20, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays from its Biotech Resurgence: Platforms and ...
CARSON CITY, Nev., April 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of an abstract from its SUNRISE-PD study on lead candidate bezisterim (NE3107) in the treatment of patients with Parkinson’s Disease at the upcoming American Academy of Neurology Annual Meeting (AAN), to be held in Chicago, IL from April 18–22, 202
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 67.9K | $95.08K | 0.00% | Added+142.4% | 2026-03-31 |
| FidelityFMR | fundamental | 0 | $0 | 0.00% | Exited | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-24upcoming | -0.52 | — | — |
| 2025-11-10 | -0.79 | -0.98 | -24.05% |
| 2025-08-15 | -3.60 | -11.05 | -206.94% |
| 2025-05-12 | -3.20 | -1.50 | +53.13% |
| 2025-02-11 | -16.00 | -4.60 | +71.25% |
| 2024-05-14 | -25.00 | -20.00 | +20.00% |
| 2024-02-13 | -27.50 | -22.00 | +20.00% |
| 2023-11-08 | -31.00 | -29.00 | +6.45% |
| 2023-08-16 | -40.00 | -23.00 | +42.50% |
| 2023-05-12 | -35.50 | -43.00 | -21.13% |
| 2023-02-10 | -25.25 | -50.00 | -98.02% |
| 2022-11-04 | -28.50 | -38.00 | -33.33% |
| 2022-09-27 | -35.67 | -33.00 | +7.48% |
| 2022-05-11 | -71.00 | -28.00 | +60.56% |
| 2022-02-08 | -41.00 | -22.00 | +46.34% |
| 2021-08-30 | -232.00 | -1018.77 | -339.12% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BIVI | -15.48% | +3.65% | +22.41% | -86.35% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -18.45% | +8.29% | +25.86% | -99.03% |